Open Label, Multicenter, Real World Practice of Durvalumab in Lung Cancer (Imfinzi PMS)

Trial Identifier: D4194R00004
Sponsor: AstraZeneca
NCTID:: NCT04068168
Start Date: January 2020
Primary Completion Date: August 2024
Study Completion Date: August 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea Ansan-si, South Korea, 15355
South Korea Anyang-si, South Korea, 431-070
South Korea Bucheon-si, South Korea, 14647
South Korea Busan, South Korea, 49267
South Korea Busan, South Korea, 49241
South Korea Changwon-si, South Korea, 51353
South Korea Cheonan, South Korea, 330-715
South Korea Daegu, South Korea, 41931
South Korea Daegu, South Korea, 41404
South Korea Goyang-si, South Korea, 10380
South Korea Gwangju, South Korea, 61453
South Korea Gyeonggi-do, South Korea, 11765
South Korea Gyeongsangnam-do, South Korea, 52727
South Korea Gyeongsangnam-do, South Korea, 50612
South Korea Hwasun-gun, South Korea, 58128
South Korea Iksan-si, South Korea, 54538
South Korea Incheon, South Korea, 405-760
South Korea Incheon, South Korea, 21431
South Korea Jeonju-si, South Korea, 54907
South Korea Pohang-si, South Korea, 37816
South Korea Seo-gu, South Korea, 49201
South Korea Seoul, South Korea, 133-792
South Korea Seoul, South Korea, 05505
South Korea Seoul, South Korea, 03722
South Korea Seoul, South Korea, 01812
South Korea Seoul, South Korea, 08308
South Korea Seoul, South Korea, 02447
South Korea Suwon-si, South Korea, 442-723
South Korea Yongin-si, South Korea, 16995